NCT05721937View on ClinicalTrials.gov

A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring

RecruitingOBSERVATIONAL

Enrollment

400

Participants

Timeline

Start Date

July 25, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Atopic Dermatitis

Interventions

DRUG

Abrocitinib

taken by mouth

Trial Locations (1)

10001

RECRUITING

Pfizer, New York

Sponsors

Lead Sponsor

Collaborators (1)

PPD Development, LP

All Listed Sponsors

collaborator

PPD Development, LP

INDUSTRY

lead

Pfizer

INDUSTRY